Department of Obstetrics and Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Am J Pathol. 2011 Sep;179(3):1385-93. doi: 10.1016/j.ajpath.2011.05.018. Epub 2011 Jul 18.
Ovarian carcinoma is the most lethal gynecologic malignancy, however underlying molecular events remain elusive. Expression of human chorionic gonadotropin β subunit (β-hCG) is clinically significant for both trophoblastic and nontrophoblastic cancers; however, whether β-hCG facilitates ovarian epithelial cell tumorigenic potential remains uncharacterized. Immortalized nontumorigenic ovarian epithelial T29 and T80 cells stably overexpressing β-hCG were examined for alterations in cell cycle and apoptotic status by flow cytometry, expression of proteins regulating cell cycle and apoptosis by Western blot, proliferation status by MTT assay, anchorage-independent colony formation, and mouse tumor formation. Immunoreactivity for β-hCG was evaluated using mouse xenografts and on human normal ovarian, fallopian tube, endometrium, and ovarian carcinoma tissues. T29 and T80 cells overexpressing β-hCG demonstrated significantly increased proliferation, anchorage-independent colony formation, prosurvival Bcl-X(L) protein expression, G2-checkpoint progression, elevated cyclins E/D1 and Cdk 2/4/6, and decreased apoptosis. Collectively, these transformational alterations in phenotype facilitated increased xenograft tumorigenesis (P < 0.05). Furthermore, β-hCG immunoreactivity was elevated in malignant ovarian tumors, compared with normal epithelial expression in ovaries, fallopian tube, and endometrium (P < 0.001). Our data indicate that elevated β-hCG transforms ovarian surface epithelial cells, facilitating proliferation, cell cycle progression, and attenuated apoptosis to promote tumorigenesis. Our results further decipher the functional role and molecular mechanism of β-hCG in ovarian carcinoma. β-hCG may contribute to ovarian cancer etiology, which introduces a new therapeutic intervention target for ovarian cancer.
卵巢癌是最致命的妇科恶性肿瘤,但潜在的分子事件仍不清楚。人绒毛膜促性腺激素β亚单位(β-hCG)的表达对滋养层和非滋养层癌症均具有重要的临床意义;然而,β-hCG 是否促进卵巢上皮细胞的肿瘤发生潜能仍未被描述。通过流式细胞术、Western blot 检测细胞周期和凋亡相关蛋白的表达、MTT 法检测细胞增殖状态、非依赖性集落形成实验和小鼠肿瘤形成实验,检测稳定过表达β-hCG的永生化非肿瘤性卵巢上皮 T29 和 T80 细胞中细胞周期和凋亡状态的变化。使用小鼠异种移植和人正常卵巢、输卵管、子宫内膜和卵巢癌组织评估β-hCG 的免疫反应性。T29 和 T80 细胞过表达β-hCG 后,增殖、非依赖性集落形成、促生存 Bcl-X(L)蛋白表达、G2 检查点进展、细胞周期蛋白 E/D1 和 Cdk 2/4/6 水平升高以及凋亡减少显著增加。总的来说,这些表型的转化改变促进了异种移植肿瘤的发生(P < 0.05)。此外,与卵巢、输卵管和子宫内膜的正常上皮表达相比,β-hCG 免疫反应性在恶性卵巢肿瘤中升高(P < 0.001)。我们的数据表明,β-hCG 的升高可转化卵巢表面上皮细胞,促进增殖、细胞周期进程和减弱凋亡,从而促进肿瘤发生。我们的研究结果进一步阐明了β-hCG 在卵巢癌中的功能作用和分子机制。β-hCG 可能导致卵巢癌的发生,为卵巢癌的治疗干预提供了新的靶点。